Controversial plans to dramatically reduce the rebate for intravitreal injections and also allow non-ophthalmologists to perform the procedure have divided Australia’s eyecare sector, with advocacy bodies considering the implications for patients. Read more
New cases of incorrectly dispensed atropine formulations have prompted calls for eyecare professionals to make annotations to scripts in order to prevent further misunderstandings among pharmacists. Read more
Associate professor Simon Skalicky has been announced as Glaucoma Australia’s (GA) new president as the organisation aims to continue its recent success of reaching the country’s glaucoma patients. Read more
Australian biotech company Opthea has reported a solid cash position to further advance clinical trials of its lead drug candidate OPT-302 in FY20, as it moves closer to imposing itself on the macular disease market. Read more
A significant Australian study into the effectiveness of Allergan’s Ozurdex implant as a treatment for Diabetic Macular Oedema (DME) has shown positive results consistent with previously published evidence. Read more
Melbourne-based biotech company Opthea has demonstrated that combination therapy involving its lead drug candidate OPT-302 is superior to standalone Lucentis treatment among neovascular age-related macular degeneration (AMD) patients. Read more
O=MEGA PREVIEW: Menicon Australia will be introducing the newest addition to the Miru family of contact lenses.The company will launch Miru 1day UpSide, the first and only silicone hydrogel daily disposable contact lens incorporated with the manufacturer’s Smart Touch technology. Read more
O=MEGA PREVIEW: Good Optical Services will display NuLids, a simple at-home dry eye treatment, as well as a new Sterileyes antibacterial feature for the Eye Doctor Hot & Cold Eye Compress product. Read more
A new research project examining the proteins that circulate in the eye’s fluids has the potential to pave the way for a test to diagnose glaucoma that doesn’t rely on intraocular pressure.
ASX-listed medical device company Visioneering Technologies (VTI) is aiming to raise up to $11.1 million in new capital after securing fresh commitments from lead investors.